They first tested the effect of monotherapy, survival was significantly prolonged in mice treated with OV-IL15C plus human CD8 T cells compared to control groups, but the same anti-tumour effect was not obtained by replacing CD8 T cells with NK cells. This evidence concerns the gene CD8A and neoplasm.